S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics

enVVeno Medical (NVNO) Stock Price, News & Analysis

$5.44
+0.16 (+3.03%)
(As of 03/28/2024 ET)
Today's Range
$5.26
$5.49
50-Day Range
$4.00
$6.65
52-Week Range
$2.51
$6.97
Volume
54,439 shs
Average Volume
182,072 shs
Market Capitalization
$72.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

enVVeno Medical MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
6.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$51,837 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.40) to ($0.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.36 out of 5 stars

Medical Sector

897th out of 938 stocks

Surgical & Medical Instruments Industry

94th out of 97 stocks

NVNO stock logo

About enVVeno Medical Stock (NASDAQ:NVNO)

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

NVNO Stock Price History

NVNO Stock News Headlines

NVNO Apr 2024 10.000 call
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Recap: enVVeno Medical Q4 Earnings
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
NVNO Jan 2024 5.000 call
enVVeno Medical reports Q3 results
See More Headlines
Receive NVNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NVNO
Employees
19
Year Founded
N/A

Profitability

Net Income
$-23,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.47 per share

Miscellaneous

Free Float
11,053,000
Market Cap
$72.46 million
Optionable
Optionable
Beta
1.20
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

NVNO Stock Analysis - Frequently Asked Questions

How have NVNO shares performed in 2024?

enVVeno Medical's stock was trading at $5.14 at the beginning of the year. Since then, NVNO shares have increased by 5.8% and is now trading at $5.44.
View the best growth stocks for 2024 here
.

When is enVVeno Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our NVNO earnings forecast
.

How were enVVeno Medical's earnings last quarter?

enVVeno Medical Corporation (NASDAQ:NVNO) released its quarterly earnings results on Thursday, February, 29th. The company reported ($0.32) earnings per share for the quarter.

Who are enVVeno Medical's major shareholders?

enVVeno Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (5.30%), Perceptive Advisors LLC (4.68%), Kingdon Capital Management L.L.C. (4.65%), Armistice Capital LLC (3.27%), Velan Capital Investment Management LP (1.29%) and Northern Trust Corp (0.28%). Insiders that own company stock include Francis Duhay, Gmt Capital Corp, Hamed Alavi, Marc H Glickman, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava.
View institutional ownership trends
.

How do I buy shares of enVVeno Medical?

Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVNO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners